{"id":"https://openalex.org/W2050657352","doi":"https://doi.org/10.1007/s40277-013-0019-2","title":"Tratamiento biol\u00f3gico de la artritis reumatoide en Espa\u00f1a. An\u00e1lisis de impacto presupuestario de la utilizaci\u00f3n de certolizumab pegol","display_name":"Tratamiento biol\u00f3gico de la artritis reumatoide en Espa\u00f1a. An\u00e1lisis de impacto presupuestario de la utilizaci\u00f3n de certolizumab pegol","publication_year":2013,"publication_date":"2013-06-28","ids":{"openalex":"https://openalex.org/W2050657352","doi":"https://doi.org/10.1007/s40277-013-0019-2","mag":"2050657352"},"language":"es","primary_location":{"id":"doi:10.1007/s40277-013-0019-2","doi":"https://doi.org/10.1007/s40277-013-0019-2","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40277-013-0019-2","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40277-013-0019-2.pdf","source":{"id":"https://openalex.org/S2764754589","display_name":"PharmacoEconomics Spanish Research Articles","issn_l":"1695-405X","issn":["1695-405X","1989-5453"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics Spanish Research Articles","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40277-013-0019-2.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006471708","display_name":"\u00c1lvaro Hidalgo\u2010Vega","orcid":"https://orcid.org/0000-0003-1031-2051","observed_orcids":["https://orcid.org/0000-0003-1031-2051"]},"institutions":[{"id":"https://openalex.org/I79189158","display_name":"University of Castilla-La Mancha","ror":"https://ror.org/05r78ng12","country_code":"ES","type":"education","lineage":["https://openalex.org/I79189158"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"\u00c1lvaro Hidalgo","raw_affiliation_strings":["Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad de Castilla la Mancha, Cobertizo San Pedro M\u00e1rtir, S/N, 45071, Toledo, Espa\u00f1a","Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad de Castilla la Mancha, Toledo, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad de Castilla la Mancha, Cobertizo San Pedro M\u00e1rtir, S/N, 45071, Toledo, Espa\u00f1a","institution_ids":["https://openalex.org/I79189158"]},{"raw_affiliation_string":"Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad de Castilla la Mancha, Toledo, Espa\u00f1a","institution_ids":["https://openalex.org/I79189158"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019094000","display_name":"Renata Villoro","orcid":"https://orcid.org/0000-0003-2880-2542","observed_orcids":["https://orcid.org/0000-0003-2880-2542"]},"institutions":[{"id":"https://openalex.org/I4210166916","display_name":"Weber","ror":"https://ror.org/05r36sv91","country_code":"ES","type":"nonprofit","lineage":["https://openalex.org/I4210166916"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Renata Villoro","raw_affiliation_strings":["Instituto Max Weber, Madrid, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Max Weber, Madrid, Espa\u00f1a","institution_ids":["https://openalex.org/I4210166916"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031518889","display_name":"Alexandra Ivanova","orcid":"https://orcid.org/0009-0004-7549-1331","observed_orcids":["https://orcid.org/0009-0004-7549-1331"]},"institutions":[{"id":"https://openalex.org/I4210166916","display_name":"Weber","ror":"https://ror.org/05r36sv91","country_code":"ES","type":"nonprofit","lineage":["https://openalex.org/I4210166916"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Alexandra Ivanova","raw_affiliation_strings":["Instituto Max Weber, Madrid, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Max Weber, Madrid, Espa\u00f1a","institution_ids":["https://openalex.org/I4210166916"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013872522","display_name":"Alberto Morell","orcid":"https://orcid.org/0000-0003-4937-4292","observed_orcids":["https://orcid.org/0000-0003-4937-4292"]},"institutions":[{"id":"https://openalex.org/I4210130498","display_name":"Hospital Universitario de La Princesa","ror":"https://ror.org/03cg5md32","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210130498","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Alberto Morell","raw_affiliation_strings":["Servicio Farmacia, Hospital La Princesa, Madrid, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Servicio Farmacia, Hospital La Princesa, Madrid, Espa\u00f1a","institution_ids":["https://openalex.org/I4210130498"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Pablo Talavera","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098039","display_name":"UCB Pharma (Spain)","ror":"https://ror.org/00t442a43","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210098039","https://openalex.org/I85722119"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pablo Talavera","raw_affiliation_strings":["Departamento M\u00e9dico, UCB Pharma, Madrid, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento M\u00e9dico, UCB Pharma, Madrid, Espa\u00f1a","institution_ids":["https://openalex.org/I4210098039"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111754366","display_name":"Bel\u00e9n Ferro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098039","display_name":"UCB Pharma (Spain)","ror":"https://ror.org/00t442a43","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210098039","https://openalex.org/I85722119"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Bel\u00e9n Ferro","raw_affiliation_strings":["Departamento de Farmacoeconom\u00eda, UCB Pharma, Madrid, Espa\u00f1a"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento de Farmacoeconom\u00eda, UCB Pharma, Madrid, Espa\u00f1a","institution_ids":["https://openalex.org/I4210098039"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5006471708"],"corresponding_institution_ids":["https://openalex.org/I79189158"],"apc_list":{"value":3140,"currency":"USD","value_usd":3140},"apc_paid":{"value":3140,"currency":"USD","value_usd":3140},"fwci":0.2158,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.5434965,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"11","issue":"3","first_page":"97","last_page":"107"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.6118000149726868,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.6118000149726868,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.35690000653266907,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.009800000116229057,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/certolizumab-pegol","display_name":"certolizumab pegol","score":0.9139999747276306},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":1.0},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.6290000081062317},{"id":"https://openalex.org/keywords/budget-impact","display_name":"budget impact","score":0.6579999923706055},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.6389999985694885},{"id":"https://openalex.org/keywords/subcutaneous-dosing","display_name":"subcutaneous dosing","score":0.5799999833106995},{"id":"https://openalex.org/keywords/spanish-national-health-system","display_name":"Spanish National Health System","score":0.625},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.5339999794960022},{"id":"https://openalex.org/keywords/treatment-utilization","display_name":"treatment utilization","score":0.34299999475479126},{"id":"https://openalex.org/keywords/cost-reduction","display_name":"cost reduction","score":0.45500001311302185},{"id":"https://openalex.org/keywords/moderate-to-severe-rheumatoid-arthritis","display_name":"moderate-to-severe rheumatoid arthritis","score":0.765999972820282}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9090756773948669},{"id":"https://openalex.org/C2776215756","wikidata":"https://www.wikidata.org/wiki/Q412909","display_name":"Certolizumab pegol","level":4,"score":0.5346936583518982},{"id":"https://openalex.org/C2781290027","wikidata":"https://www.wikidata.org/wiki/Q413879","display_name":"Golimumab","level":4,"score":0.47810763120651245},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.4282046854496002},{"id":"https://openalex.org/C15708023","wikidata":"https://www.wikidata.org/wiki/Q80083","display_name":"Humanities","level":1,"score":0.33608055114746094},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.19692832231521606},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.06647753715515137},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.06240344047546387},{"id":"https://openalex.org/C142362112","wikidata":"https://www.wikidata.org/wiki/Q735","display_name":"Art","level":0,"score":0.03818666934967041}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1007/s40277-013-0019-2","doi":"https://doi.org/10.1007/s40277-013-0019-2","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40277-013-0019-2","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40277-013-0019-2.pdf","source":{"id":"https://openalex.org/S2764754589","display_name":"PharmacoEconomics Spanish Research Articles","issn_l":"1695-405X","issn":["1695-405X","1989-5453"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics Spanish Research Articles","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1007/s40277-013-0019-2","doi":"https://doi.org/10.1007/s40277-013-0019-2","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40277-013-0019-2","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40277-013-0019-2.pdf","source":{"id":"https://openalex.org/S2764754589","display_name":"PharmacoEconomics Spanish Research Articles","issn_l":"1695-405X","issn":["1695-405X","1989-5453"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics Spanish Research Articles","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8371999859809875,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2050657352.pdf","grobid_xml":"https://content.openalex.org/works/W2050657352.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W80057167","https://openalex.org/W2006566716","https://openalex.org/W2055481383","https://openalex.org/W2062358720","https://openalex.org/W2088370035","https://openalex.org/W2091286035","https://openalex.org/W2091732273","https://openalex.org/W2099199787","https://openalex.org/W2118420318","https://openalex.org/W2125501404","https://openalex.org/W2126502186","https://openalex.org/W2150486920","https://openalex.org/W2162254515","https://openalex.org/W2163817180","https://openalex.org/W4211172841"],"related_works":["https://openalex.org/W2136484694","https://openalex.org/W2317357740","https://openalex.org/W1982205236","https://openalex.org/W2010555981","https://openalex.org/W2752861844","https://openalex.org/W1924152535","https://openalex.org/W1934028877","https://openalex.org/W2763496631","https://openalex.org/W7063977960","https://openalex.org/W1516475269"],"abstract_inverted_index":{"Estimar":[0],"el":[1,128,150,175,244,248],"impacto":[2],"presupuestario":[3],"(IP)":[4],"en":[5,28,149,164,168,183,236,243,247],"Espa\u00f1a":[6,184,237],"del":[7,56,143,223],"uso":[8],"combinado":[9],"de":[10,17,26,45,59,66,98,104,112,115,124,130,140,154,161,180,192,195,205,208,213,215,217,227,232],"certolizumab":[11,158,181,239],"pegol":[12,159,182,240],"(siguiendo":[13],"un":[14,51,63,122],"r\u00e9gimen":[15],"fijo":[16],"dosis":[18,25,218],"subcut\u00e1neas":[19],"cada":[20],"2":[21,32],"semanas,":[22],"tras":[23],"una":[24,138],"inducci\u00f3n":[27],"las":[29,146],"semanas":[30],"0,":[31],"y":[33,92,101,114,135,210],"4)":[34],"m\u00e1s":[35],"metotrexato":[36],"(MTX),":[37],"como":[38],"terapia":[39,77],"para":[40,83],"la":[41,54,72,84,102,152,178,203,211],"artritis":[42],"reumatoide":[43],"(AR)":[44],"moderada":[46,233],"a":[47,75,79,96,166,202,234],"grave.":[48],"Se":[49,70,107,120],"dise\u00f1\u00f3":[50],"modelo":[52,171],"desde":[53],"perspectiva":[55],"Sistema":[57],"Nacional":[58],"Salud":[60],"(SNS)":[61],"con":[62,132,157,230,238],"horizonte":[64],"temporal":[65],"5":[67],"a\u00f1os":[68],"(2013\u20132017).":[69],"estim\u00f3":[71],"poblaci\u00f3n":[73],"candidata":[74],"esta":[76],"frente":[78],"otras":[80],"terapias":[81],"biol\u00f3gicas":[82],"AR":[85,231],"([abatacept,":[86],"adalimumab,":[87],"etanercept,":[88],"infliximab,":[89],"tocilizumab,":[90],"golimumab":[91],"rituximab]":[93],"+":[94],"[MTX])":[95],"partir":[97],"informaci\u00f3n":[99],"epidemiol\u00f3gica":[100],"revisi\u00f3n":[103],"publicaciones":[105],"cient\u00edficas.":[106],"incluyeron":[108],"los":[109,206,228],"costes:":[110],"farmacol\u00f3gicos,":[111],"administraci\u00f3n":[113,209],"monitorizaci\u00f3n":[116],"(a\u00f1o":[117],"base":[118],"2013).":[119],"realiz\u00f3":[121],"an\u00e1lisis":[123],"sensibilidad":[125],"univariante":[126],"sobre":[127],"conjunto":[129],"variables":[131],"mayor":[133],"incertidumbre":[134],"se":[136],"aplic\u00f3":[137],"tasa":[139],"descuento":[141],"anual":[142],"3%.":[144],"Con":[145],"asunciones":[147],"hechas":[148],"modelo,":[151],"cifra":[153],"pacientes":[155,163,229],"tratados":[156],"evolucionar\u00eda":[160],"1.943":[162],"2013":[165],"6.234":[167],"2017.":[169],"El":[170,225],"estima":[172],"que":[173],"durante":[174],"per\u00edodo":[176,249],"2013\u20132017":[177],"utilizaci\u00f3n":[179],"generar\u00eda":[185],"unos":[186],"ahorros":[187,198,242],"globales":[188],"medios":[189],"por":[190,221],"valor":[191],"10,26":[193],"millones":[194],"euros.":[196],"Dichos":[197],"ser\u00edan":[199],"debidos":[200],"fundamentalmente":[201],"reducci\u00f3n":[204],"costes":[207],"ausencia":[212],"necesidad":[214],"intensificaci\u00f3n":[216],"o":[219],"ajustes":[220],"peso":[222],"paciente.":[224],"tratamiento":[226],"grave":[235],"permitir\u00eda":[241],"SNS":[245],"espa\u00f1ol":[246],"2013\u20132017.":[250]},"counts_by_year":[{"year":2015,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}